WEIGHT & METABOLIC RESEARCH

Retatrutide

Studied for some of the strongest weight-loss and metabolic effects recorded for a peptide, by acting on three appetite and energy pathways at once.

Retatrutide is an investigational peptide that engages three receptors at the same time: GLP-1 and GIP, the gut-hormone pathways that govern appetite and blood sugar, and glucagon, which governs how much energy the body burns. Phase 3 trials have completed, reporting large reductions in body weight alongside broad metabolic improvements, and it has been in active research-market use for roughly two years. It is not FDA-approved.

GLP-1 / GIP / GlucagonWeight & MetabolicAppetite RegulationInsulin Sensitivity

Why BLP features Retatrutide

Included because it pairs completed Phase 3 human evidence with a specific, well-characterized triple-receptor mechanism and roughly two years of consistent research-market use. It represents the strongest end of the metabolic-research spectrum while remaining investigational.

Mechanism

Engages three metabolic receptors at once: GLP-1 (appetite and gastric emptying), GIP (fat-tissue insulin sensitivity), and glucagon (energy expenditure and fat oxidation).

The glucagon component is the differentiator from GLP-1/GIP-only compounds, adding a metabolic-rate and fat-oxidation dimension alongside appetite reduction.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

Phase 3 TRIUMPH trials reported average weight loss of 28.7% at 68 weeks at the 12mg dose (TRIUMPH-4), reaching an average of 30.3% by 104 weeks (TRIUMPH-1), after Phase 2 reported 24.2% at 48 weeks.
Studies reported large reductions in liver fat, improved HbA1c, and improvements in triglycerides, cholesterol, and blood pressure.
Reported effects on osteoarthritic pain in some study populations.
GI side effects (nausea, vomiting, diarrhea, constipation) were mostly mild to moderate and tended to improve over time.

Mechanistic & supporting research

Mechanism established through receptor pharmacology across the GLP-1, GIP, and glucagon pathways.
Triple-agonism modeled as producing additive appetite, insulin-sensitivity, and energy-expenditure effects.

Regulatory status

Retatrutide is investigational and not FDA-approved for any indication. Phase 3 clinical development has completed. Sold and offered strictly for laboratory and research use.

Related research

Tirzepatide Cagrilintide Tesamorelin Evidence Framework Research Library